menu
    • menu
    [{"orgOrder":0,"company":"SiSaf","sponsor":"CSSi LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"SIS-101-ADO","moa":"CLCN7 gene mutation","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ CSSi LifeSciences","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ CSSi LifeSciences"},{"orgOrder":0,"company":"SiSaf","sponsor":"University of Leipzig","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"miR24-3p","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ University of Leipzig","highestDevelopmentStatusID":"4","companyTruncated":"SiSaf \/ University of Leipzig"},{"orgOrder":0,"company":"SiSaf","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"SIS-101-ADO","moa":"","graph1":"Musculoskeletal","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"SiSaf \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by SiSaf

    Menu

    SiSaf

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SiSaf

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SiSaf

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIS-101-ADO

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease D...

                            Details : SIS-101-ADO is an siRNA that suppresses the expression of CLCN7, a mutant gene expressed by osteoclasts and other cell types responsible for causing ADO2, the RNA therapy restores bone mass and quality to nearly normal levels.

                            Brand Name : SIS-101-ADO

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : SIS-101-ADO

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SiSaf

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SiSaf

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : miR506-3p,miR24-3p

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : University of Leipzig

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancrea...

                            Details : The collaboration will combine SiSaf’s expertise in RNA delivery using its Bio-Courier sshLNPs and the University of Leipzig’s expertise in miRNA targeting and therapeutic approaches in cancer, with an initial focus on pancreatic cancer to develop mi...

                            Brand Name : Undislcosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 02, 2023

                            Lead Product(s) : miR506-3p,miR24-3p

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : University of Leipzig

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SiSaf

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            SiSaf

                            United Kingdom arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SIS-101-ADO

                            Therapeutic Area : Musculoskeletal

                            Study Phase : IND Enabling

                            Sponsor : CSSi LifeSciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SiSaf's Innovative RNA Therapeutic for Rare Genetic Skeletal Disorders Begins the U.S. Regulatory Process for ...

                            Details : SIS-101-ADO combines an siRNA that suppress expression of CLCN7, with SiSaf’s Bio-Courier® next generation silicon stabilized hybrid lipid nanoparticles technology of other RNA delivery technologies by merging LNP technology with inorganic bioabsorbab...

                            Brand Name : SIS-101-ADO

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 12, 2022

                            Lead Product(s) : SIS-101-ADO

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : IND Enabling

                            Sponsor : CSSi LifeSciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth